VolitionRx Appoints New CSO, Board Member
Ticker: VNRX · Form: 8-K · Filed: Apr 26, 2024 · CIK: 93314
Sentiment: neutral
Topics: leadership-change, board-appointment, corporate-governance
Related Tickers: VNRX
TL;DR
VolitionRx just snagged a new CSO and board member, Dr. Bearss. Big science moves ahead.
AI Summary
VolitionRx Limited announced on April 24, 2024, a change in its board of directors, with the appointment of Dr. David E. Bearss as Chief Scientific Officer and a member of the Board. Additionally, the company reported on its financial statements and exhibits, and potential amendments to its articles of incorporation or bylaws.
Why It Matters
The appointment of a new Chief Scientific Officer with board representation suggests a strategic focus on scientific innovation and leadership within VolitionRx.
Risk Assessment
Risk Level: medium — Changes in key leadership and potential amendments to corporate structure can introduce uncertainty and impact future strategic direction.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- Dr. David E. Bearss (person) — Appointed Chief Scientific Officer and Board Member
- April 24, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Scientific Officer and Board Member?
Dr. David E. Bearss has been appointed as the new Chief Scientific Officer and a member of the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 24, 2024.
What are the main items reported in this Form 8-K?
This Form 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, amendments to articles of incorporation or bylaws, change in fiscal year, and financial statements and exhibits.
In which state is VolitionRx Limited incorporated?
VolitionRx Limited is incorporated in Delaware.
What is the business address of VolitionRx Limited?
The business address is 1489 West Warm Springs Road, Suite 110, Henderson, NV 89014.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-04-26 16:06:42
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 VNRX NYSE American, LLC Indicate b
Filing Documents
- vnrx_8k.htm (8-K) — 29KB
- vnrx_ex31.htm (EX-3.1) — 5KB
- 0001477932-24-002348.txt ( ) — 158KB
- vnrx-20240424.xsd (EX-101.SCH) — 6KB
- vnrx-20240424_lab.xml (EX-101.LAB) — 15KB
- vnrx-20240424_cal.xml (EX-101.CAL) — 1KB
- vnrx-20240424_pre.xml (EX-101.PRE) — 9KB
- vnrx-20240424_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On April 24, 2024, the Board adopted resolutions to amend the Company's Bylaws to provide that the holders of 33 1/3% of the voting power of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, will constitute a quorum at all meetings of the stockholders for the transaction of business; and where a separate vote by a class or series or classes or series is required, the holders of 33 1/3% of the voting power of the issued and outstanding shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter. The Company's Bylaws previously provided that the holders of a majority of the voting power of the stock issued and outstanding (and with respect to a separate class or series vote, just such class or series) and entitled to vote, present in person or represented by proxy, would constitute a quorum at all meetings of the stockholders for the transaction of business. The foregoing description of the amendment to the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment of the Amended and Restated Bylaws, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Number Description 3.1 Certificate of Amendment of the Amended and Restated Bylaws 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: April 26, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer and President 3